Recently, the GLP-1/GIP co-agonist, tirzepatide, was approved by the US Food and Drug Administration (FDA) for use in patients with obesity after it was found to induce substantial weight loss in the SURMOUNT-1 trial, inducing a 19.5% reduction in weight loss compared to a 3.1% reduction in patients receiving a placebo [66]. The gene discussed is GLP1R; the disease is Obesity.